ArticleCureus2026
Efficacy of Low-Density Lipoprotein Apheresis in an Adult Case of Recurrent Focal Segmental Glomerulosclerosis Post-kidney Transplant.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence of focal segmental glomerulosclerosis (FSGS) in the transplanted kidney has been reported in renal transplant cases. The management often involves therapeutic plasma exchange (TPE) and immunomodulatory therapies with a variable response. In patients with FSGS, dyslipidemia can contribute to irreversible renal injury. We present a 26-year-old man with recurrent FSGS in his second transplanted kidney which was controlled partially with aggressive TPE for over 3.5 years. He achieved complete remission following the completion of the low-density lipoprotein apheresis (LDL-A) protocol which consists of two procedures per week for three consecutive weeks, followed by one procedure per week for the 12 consecutive weeks (total of 18 procedures). He has been in remission for over four years after a single course of LDL-A. This report supports the use of LDL-A for recurrent FSGS post-kidney transplant in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.